The results could pave the way for Datroway to supplant chemotherapy in certain triple-negative tumors, adding to existing clearances in other breast and lung malignancies.

The results are the latest setback for weight loss medicines that target a kind of cannabinoid receptor and are meant to boost the effects of incretin therapies like Wegovy.

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that autoimmune diseases affect 400 to 600 million people worldwide, with the burden ...

The Italian drugmaker will pay as much as $115 million in upfront and near-term payments in a deal that gives it rights to a treatment in early-stage testing for primary hyperoxaluria type 1.

Implementing artificial intelligence requires significant human labor and technical expertise, threatening to create a digital divide between highly resourced health systems and safety-net providers.

The decision to clear another mifepristone generic sparked political backlash. Elsewhere, Medicare delayed a decision on whether to subject “combination” drugs to pricing negotiations, and a cancer ...

In a first-of-its-kind finding, Amgen’s PCSK9 drug protected heart health when tested as a “primary prevention” therapy, which could pave the way for access to a much broader population.

The company has received a “limited number” of non-binding proposals, mostly from groups of financial investors, for a business that was once its primary focus.

The company is working on T cell engagers and other multifunctional antibodies, led by a prospect it believes might be helpful treating the vast majority of colorectal cancer cases.

Wall Street analysts expect the subcutaneous version of Keytruda, which just launched this week, to help soften the blow when the original loses patent protection later this decade.

The Japanese pharmaceutical company, which had made cell therapy a priority a few years ago, aims to partner its work while prioritizing investments elsewhere.

Medical meetings often feature important clinical trial results, making them barometers of biotech and pharma companies’ research progress. Here’s a list of conferences to watch next year.